LRRC29 Inhibitors

WZB117 and Triciribine target metabolic and signaling pathways, respectively, which can have downstream effects on proteins regulated by these pathways, including LRRC29. These inhibitors act by altering the cellular environment or signaling mechanisms in which LRRC29 is involved. U0126, LY294002, and Rapamycin are examples of kinase inhibitors that can change the phosphorylation status of numerous proteins and signaling cascades that may intersect with LRRC29 function.

SB431542 and DAPT are specific pathway inhibitors that can modify the TGF-β and Notch signaling pathways, respectively, potentially altering processes that govern the regulation of LRRC29. Additionally, compounds like XAV-939 and BIX 01294, which inhibit Tankyrase and G9a respectively, represent molecules that can affect the Wnt/β-catenin pathway and epigenetic regulation mechanisms, possibly impacting LRRC29 expression patterns. Other chemicals such as ZM 447439, PD0332991, and Y-27632 target cell division and cytoskeletal dynamics, providing a broad range of mechanisms that can indirectly influence the role of LRRC29 in cellular processes.